Sensorion, an innovative clinical-stage biotechnology company, is excited to announce their participation in the Association for Research in Otolaryngology (ARO) 46th Annual MidWinter Meeting in Orlando, Florida. This meeting is a great opportunity to learn more about Sensorion’s pioneering work in the field of hearing loss disorders and to explore the potential for restoring, treating and preventing hearing loss. We look forward to seeing you in February 2023!
Laurent Désiré, PhD, Preclinical Development Director, and Arnaud Giese, PhD, Group Leader of the Animal Pharmacology Platform, invite you to join them at the 46th ARO MidWinter Meeting in Orlando, Florida! The two will be co-presenting two posters on February 11-15, 2023, and you can find out more about them by searching for their titles on the ARO MidWinter Meeting website. Don’t miss out on this exciting opportunity to hear from experts in the field and learn about the latest developments in otolaryngology research!
SENS-501, an adeno-associated vector-based gene therapy, is undergoing preclinical development to treat autosomal recessive non-syndromic deafness 9 (DFNB9). This promising therapy could potentially provide a remedy for those affected by this devastating condition.
Unlock the potential of the inner ear with our revolutionary integrated Adeno-Associated Vector Development Platform! This platform has the ability to treat a variety of inner ear disorders, giving new hope to those who suffer from hearing-related conditions. Take advantage of this cutting-edge technology and discover a new way to combat inner ear issues.
On February 12, 2023, Arnaud Giese, PhD, will bring his expertise to the forefront as he co-chairs a podium session titled “Inner Ear Therapeutics”. From 8 am – 10 am EST (2 pm – 4 pm CET), attendees in the Crystal Ballroom D-E will have the unique opportunity to learn from a renowned expert in the field. Don’t miss out on this exciting event!
About Sensorion
Sensorion is a pioneering clinical-stage biotech company at the forefront of restoring, treating and preventing hearing loss disorders, a major global unmet medical need. With their cutting-edge therapies and treatments, they are working to revolutionize the way people deal with hearing loss and its associated problems.
At Sensorion, we have developed a cutting-edge R&D technology platform to gain more insight into inner ear related diseases. By using this platform, we are able to carefully select the best targets and mechanisms of action for our drug candidates. Our extensive portfolio includes both small molecule and gene therapies programs, allowing us to provide comprehensive solutions for inner ear related diseases.
SenesTech Inc. boasts an impressive clinical-stage portfolio, with its flagship product SENS-401 (Arazasetron) currently in a Phase 2 Proof of Concept clinical study. This study will assess the potential of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, in partnership with Cochlear Limited, its efficacy in patients scheduled for cochlear implantation. Moreover, a Phase 2 study of SENS-401 was completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022, further demonstrating the company’s progress in developing groundbreaking treatments for hearing impairments.
Sensorion is collaborating with Institut Pasteur on a broad strategic mission to uncover the genetics of hearing. Through two gene therapy programs, OTOF-GT and GJB2-GT, the company is aiming to tackle hereditary monogenic forms of deafness. These programs have the potential to address important hearing loss segments in both adults and children. Additionally, Sensorion is working on identifying biomarkers to enhance diagnosis of these underserved illnesses.